Correlation Between Crispr Therapeutics and Stoke Therapeutics
Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and Stoke Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and Stoke Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crispr Therapeutics AG and Stoke Therapeutics, you can compare the effects of market volatilities on Crispr Therapeutics and Stoke Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of Stoke Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and Stoke Therapeutics.
Diversification Opportunities for Crispr Therapeutics and Stoke Therapeutics
0.03 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Crispr and Stoke is 0.03. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and Stoke Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Stoke Therapeutics and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with Stoke Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Stoke Therapeutics has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and Stoke Therapeutics go up and down completely randomly.
Pair Corralation between Crispr Therapeutics and Stoke Therapeutics
Given the investment horizon of 90 days Crispr Therapeutics AG is expected to generate 0.9 times more return on investment than Stoke Therapeutics. However, Crispr Therapeutics AG is 1.11 times less risky than Stoke Therapeutics. It trades about 0.03 of its potential returns per unit of risk. Stoke Therapeutics is currently generating about -0.06 per unit of risk. If you would invest 5,076 in Crispr Therapeutics AG on September 2, 2024 and sell it today you would earn a total of 41.00 from holding Crispr Therapeutics AG or generate 0.81% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Crispr Therapeutics AG vs. Stoke Therapeutics
Performance |
| Timeline |
| Crispr Therapeutics |
| Stoke Therapeutics |
Crispr Therapeutics and Stoke Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Crispr Therapeutics and Stoke Therapeutics
The main advantage of trading using opposite Crispr Therapeutics and Stoke Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, Stoke Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Stoke Therapeutics will offset losses from the drop in Stoke Therapeutics' long position.| Crispr Therapeutics vs. Beam Therapeutics | Crispr Therapeutics vs. Editas Medicine | Crispr Therapeutics vs. Caribou Biosciences | Crispr Therapeutics vs. Verve Therapeutics |
| Stoke Therapeutics vs. Tff Pharmaceuticals | Stoke Therapeutics vs. Eliem Therapeutics | Stoke Therapeutics vs. Inhibrx | Stoke Therapeutics vs. Enliven Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Complementary Tools
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |